Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
Julie R. Brahmer(Johns Hopkins University), Suresh S. Ramalingam(Emory University), Laura J. Eccles(Bristol-Myers Squibb (United States)), Clarisse Audigier-Valette(Hôpital d'Instruction des Armées Sainte-Anne), Adam Płużański(The Maria Sklodowska-Curie National Research Institute of Oncology), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Hossein Borghaei(Fox Chase Cancer Center), Mauricio Mahave(Fundación Arturo López Pérez), Kenneth J. O’Byrne(Translational Research Institute), Randeep Sangha, Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Lorena Lupinacci(Hospital Italiano de Buenos Aires), László Urbán(University of Matanzas), Ravi G. Gupta(Bristol-Myers Squibb (United States)), Martin Reck(German Center for Lung Research), Steven I. Blum(Bristol-Myers Squibb (United States)), Makoto Nishio(Japanese Foundation For Cancer Research), Li Li(The University of Texas MD Anderson Cancer Center), Jong-Seok Lee(Seoul National University Bundang Hospital), Jacobus A. Burgers(The Netherlands Cancer Institute), Judith Bushong(Bristol-Myers Squibb (United States)), Samreen Ahmed(University Hospitals of Leicester NHS Trust), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta)
Cited by 375
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k